Abeona Therapeutics’ (ABEO) “Hold” Rating Reaffirmed at Mizuho

Mizuho reaffirmed their hold rating on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research report report published on Thursday morning, AnalystRatings.com reports. Mizuho currently has a $4.00 price target on the biopharmaceutical company’s stock.

Several other research analysts also recently commented on ABEO. Royal Bank of Canada lowered their target price on Abeona Therapeutics to $16.00 and set a positive rating for the company in a research note on Tuesday, August 13th. They noted that the move was a valuation call. Cantor Fitzgerald reissued a neutral rating on shares of Abeona Therapeutics in a research note on Friday, October 18th. ValuEngine raised Abeona Therapeutics from a hold rating to a buy rating in a research note on Wednesday, October 2nd. Maxim Group cut Abeona Therapeutics from a buy rating to a hold rating in a report on Thursday, August 15th. Finally, HC Wainwright reiterated a buy rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Abeona Therapeutics presently has an average rating of Hold and an average target price of $13.30.

Shares of ABEO traded down $0.09 during midday trading on Thursday, reaching $2.23. 147,900 shares of the stock were exchanged, compared to its average volume of 649,424. Abeona Therapeutics has a twelve month low of $1.46 and a twelve month high of $9.55. The company has a quick ratio of 2.54, a current ratio of 2.45 and a debt-to-equity ratio of 0.07. The company has a market cap of $116.12 million, a P/E ratio of -1.87 and a beta of 2.02. The stock’s 50 day simple moving average is $2.40 and its 200 day simple moving average is $3.89.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.44) by $0.09. As a group, analysts predict that Abeona Therapeutics will post -1.68 earnings per share for the current year.

A number of hedge funds have recently made changes to their positions in ABEO. Tower Research Capital LLC TRC lifted its stake in Abeona Therapeutics by 434.6% in the second quarter. Tower Research Capital LLC TRC now owns 8,719 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 7,088 shares during the period. Ellington Management Group LLC acquired a new position in Abeona Therapeutics in the second quarter valued at approximately $50,000. Trexquant Investment LP acquired a new position in Abeona Therapeutics in the second quarter valued at approximately $53,000. D. E. Shaw & Co. Inc. acquired a new position in Abeona Therapeutics in the second quarter valued at approximately $59,000. Finally, Marshall Wace LLP lifted its stake in Abeona Therapeutics by 45.9% in the second quarter. Marshall Wace LLP now owns 13,254 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 4,168 shares during the period. Institutional investors and hedge funds own 59.27% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Read More: What does an inverted yield curve signify?

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.